Alembic Pharmaceuticals Ltd. announces successful USFDA inspection at Aleor Dermaceuticals Ltd.
Deepthi | Myequity news | Date : 22-10-2018 10:40:00 IST
Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has successfully cleared its first United States Food and Drugs Administration (USFDA) inspection of its new formulation manufacturing facility located at Karakhadi, Gujarat, India; without any observations. The scheduled inspection was carried out between 15th October, 2018 and 19th October, 2018.
"We are very pleased to see Aleor make tremendous progress since inception and congratulate the entire team at Aleor for successfully clearing its first inspection", said Mr. Pranav Amin, Managing Director of Alembic.
"This is a result of the dedication, commitment and focus of the entire Aleor team to ensure highest quality standards are maintained and we are very excited to build this organisation on a global platform", said Dr. M S Mohan, Founder and Managing Director of Orbicular.
About Alembic Pharmaceuticals Limited:
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India.